Literature DB >> 16210406

Global gene expression profile of human cord blood-derived CD133+ cells.

Taina Jaatinen1, Heidi Hemmoranta, Sampsa Hautaniemi, Jari Niemi, Daniel Nicorici, Jarmo Laine, Olli Yli-Harja, Jukka Partanen.   

Abstract

Human cord blood (CB)-derived CD133+ cells carry characteristics of primitive hematopoietic cells and proffer an alternative for CD34+ cells in hematopoietic stem cell (HSC) transplantation. To characterize the CD133+ cell population on a genetic level, a global expression analysis of CD133+ cells was performed using oligonucleotide microarrays. CD133+ cells were purified from four fresh CB units by immunomagnetic selection. All four CD133+ samples showed significant similarity in their gene expression pattern, whereas they differed clearly from the CD133- control samples. In all, 690 transcripts were differentially expressed between CD133+ and CD133- cells. Of these, 393 were increased and 297 were decreased in CD133+ cells. The highest overexpression was noted in genes associated with metabolism, cellular physiological processes, cell communication, and development. A set of 257 transcripts expressed solely in the CD133+ cell population was identified. Colony-forming unit (CFU) assay was used to detect the clonal progeny of precursors present in the studied cell populations. The results demonstrate that CD133+ cells express primitive markers and possess clonogenic progenitor capacity. This study provides a gene expression profile for human CD133+ cells. It presents a set of genes that may be used to unravel the properties of the CD133+ cell population, assumed to be highly enriched in HSCs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210406     DOI: 10.1634/stemcells.2005-0185

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  49 in total

1.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Authors:  Sun-Mi Park; Mithat Gönen; Ly Vu; Gerard Minuesa; Patrick Tivnan; Trevor S Barlowe; James Taggart; Yuheng Lu; Raquel P Deering; Nir Hacohen; Maria E Figueroa; Elisabeth Paietta; Hugo F Fernandez; Martin S Tallman; Ari Melnick; Ross Levine; Christina Leslie; Christopher J Lengner; Michael G Kharas
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

2.  Correlation of dyskerin expression with active proliferation independent of telomerase.

Authors:  Faizan Alawi; Ping Lin; Barry Ziober; Reena Patel
Journal:  Head Neck       Date:  2010-12-08       Impact factor: 3.147

3.  Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.

Authors:  Dmitry Borkin; Shihan He; Hongzhi Miao; Katarzyna Kempinska; Jonathan Pollock; Jennifer Chase; Trupta Purohit; Bhavna Malik; Ting Zhao; Jingya Wang; Bo Wen; Hongliang Zong; Morgan Jones; Gwenn Danet-Desnoyers; Monica L Guzman; Moshe Talpaz; Dale L Bixby; Duxin Sun; Jay L Hess; Andrew G Muntean; Ivan Maillard; Tomasz Cierpicki; Jolanta Grembecka
Journal:  Cancer Cell       Date:  2015-03-26       Impact factor: 31.743

4.  Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy.

Authors:  Byung-Sik Cho; Zhihong Zeng; Hong Mu; Zhiqiang Wang; Sergej Konoplev; Teresa McQueen; Marina Protopopova; Jorge Cortes; Joseph R Marszalek; Sheng-Bin Peng; Wencai Ma; R Eric Davis; Donald E Thornton; Michael Andreeff; Marina Konopleva
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

5.  The SKI proto-oncogene enhances the in vivo repopulation of hematopoietic stem cells and causes myeloproliferative disease.

Authors:  Sofie Singbrant; Meaghan Wall; Jennifer Moody; Göran Karlsson; Alistair M Chalk; Brian Liddicoat; Megan R Russell; Carl R Walkley; Stefan Karlsson
Journal:  Haematologica       Date:  2014-01-10       Impact factor: 9.941

6.  Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13.

Authors:  Suzan Imren; Michael Heuser; Maura Gasparetto; Philip A Beer; Gudmundur L Norddahl; Ping Xiang; Ling Chen; Tobias Berg; Garrett W Rhyasen; Patricia Rosten; Gyeongsin Park; Yeonsook Moon; Andrew P Weng; Connie J Eaves; R Keith Humphries
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

7.  Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia.

Authors:  Dan A Landau; Kendell Clement; Michael J Ziller; Patrick Boyle; Jean Fan; Hongcang Gu; Kristen Stevenson; Carrie Sougnez; Lili Wang; Shuqiang Li; Dylan Kotliar; Wandi Zhang; Mahmoud Ghandi; Levi Garraway; Stacey M Fernandes; Kenneth J Livak; Stacey Gabriel; Andreas Gnirke; Eric S Lander; Jennifer R Brown; Donna Neuberg; Peter V Kharchenko; Nir Hacohen; Gad Getz; Alexander Meissner; Catherine J Wu
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

8.  The integrin alpha9beta1 on hematopoietic stem and progenitor cells: involvement in cell adhesion, proliferation and differentiation.

Authors:  Thomas D Schreiber; Carolin Steinl; Mike Essl; Harald Abele; Konstanze Geiger; Claudia A Müller; Wilhelm K Aicher; Gerd Klein
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

9.  An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation.

Authors:  William Marion; Steffen Boettcher; Sonya Ruiz-Torres; Edroaldo Lummertz da Rocha; Vanessa Lundin; Vivian Morris; Stephanie Chou; Anna M Zhao; Caroline Kubaczka; Olivia Aumais; Yosra Zhang; Akiko Shimamura; Thorsten M Schlaeger; Trista E North; Benjamin L Ebert; Susanne I Wells; George Q Daley; R Grant Rowe
Journal:  Blood Adv       Date:  2020-10-13

10.  MEIS1 regulates early erythroid and megakaryocytic cell fate.

Authors:  Sabrina Zeddies; Sjoert B G Jansen; Franca di Summa; Dirk Geerts; Jaap J Zwaginga; C Ellen van der Schoot; Marieke von Lindern; Daphne C Thijssen-Timmer
Journal:  Haematologica       Date:  2014-08-08       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.